Quanta Therapeutics wins FDA Fast Track for KRAS G12D drug QTX3034

Quanta Therapeutics has received FDA Fast Track designation for QTX3034, its oral, G12D-preferring multi-KRAS inhibitor, for the treatment of KRAS G12D-mutant colorectal cancer in combination with the anti-EGFR antibody cetuximab, with or without FOLFOX chemotherapy. The privately held, clinical-stage company simultaneously announced that preliminary clinical combination data for the same treatment regimens would be presented at the European Society for Medical Oncology Annual Congress in Madrid on 24 October 2026.

The Fast Track designation was granted on the basis of clinical data, which Quanta's chief executive Perry Nisen said the company believes makes QTX3034 the first KRAS G12D-targeted therapy in colorectal cancer to have earned the designation through that route. Fast Track status provides more frequent FDA dialogue on trial design and data packages, enables rolling NDA submission, and creates eligibility for priority review if relevant criteria are met at the time of filing.

Clinical data and trial context

The ESMO presentation, assigned abstract number 790RO in the rapid oral gastrointestinal tumours session, covers preliminary results of QTX3034 in KRAS G12D-mutant colorectal cancer patients treated in combination with cetuximab with or without modified FOLFOX6 chemotherapy. Quanta did not release the data ahead of the congress, so response rates, progression-free survival figures and safety data remain undisclosed at this stage.

KRAS G12D is among the most common oncogenic mutations in colorectal cancer, present in roughly 10 to 13 per cent of all CRC cases according to published genomic analyses. Until recently, KRAS was considered undruggable, and the approval of sotorasib and adagrasib for KRAS G12C-mutant non-small cell lung cancer demonstrated that selective covalent inhibition of specific KRAS variants is therapeutically viable. The G12D variant, however, does not carry the reactive cysteine that those covalent inhibitors exploit, making non-covalent approaches necessary and technically more demanding.

Competitive landscape

Quanta is not alone in pursuing KRAS G12D. Mirati Therapeutics, Revolution Medicines, and a number of university-spinout companies have active programmes targeting this mutation across different tumour types, and the field is increasingly crowded at the preclinical and early clinical stages. What distinguishes QTX3034 in Quanta's characterisation is its Second Harmonic Generation platform, which the company uses to identify allosteric modulators of RAS protein complexes rather than blocking the nucleotide-binding site directly. Whether that structural differentiation translates into a clinically meaningful advantage over competing approaches will be one of the key questions investors and oncologists will ask when the full dataset appears.

The combination with cetuximab is also strategically notable. Anti-EGFR antibodies such as cetuximab are standard of care in RAS wild-type metastatic colorectal cancer but are contraindicated in KRAS-mutant disease precisely because downstream RAS activation negates their effect. A KRAS inhibitor capable of suppressing G12D activity could, in principle, resensitise tumours to EGFR blockade, creating a mechanistically rational vertical combination. Clinical validation of that hypothesis at ESMO would substantially strengthen Quanta's competitive position and regulatory narrative.

Full clinical data from the ESMO presentation, alongside forthcoming FDA interactions enabled by Fast Track status, will be the near-term catalysts for Quanta as it determines next steps in its development programme.